Phase III study of cell-based therapy for venous leg ulcers

  Healthpoint Biotherapeutics (Fort Worth, TX) announced the initiation of a Phase lll clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802- 247 plus compression therapy compared to those receiving vehicle control plus compression therapy over the 12-week treatment period.

  The North American study is a randomized, double-blind study involving subjects 18 years of age and older with venous leg ulcers of at least 6 weeks but not more than 24 months duration. The ulcers must be between 2 cm2 and 12 cm2 in area at presentation. Approximately 440 subjects will be enrolled across 45 investigational centers in the United States and Canada.

  For more information, visit www.healthpointbio.com.

image description image description